Protagenic Therapeutics (PTIX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Protagenic Therapeutics (PTIX) has a cash flow conversion efficiency ratio of 0.087x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-410.42K) by net assets ($-4.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PTIX company net worth for the company's overall valuation and market capitalisation.
Protagenic Therapeutics - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how Protagenic Therapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Protagenic Therapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Protagenic Therapeutics ranked by their cash flow conversion efficiency. Explore Protagenic Therapeutics cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Grupo Vasconia S.A.B
MX:VASCONI
|
0.006x |
|
Distribution Finance Capital Holdings PLC
LSE:DFCH
|
0.088x |
|
Cho Thavee Public Company Limited
BK:CHO
|
-0.006x |
|
Reneuco Berhad
KLSE:7130
|
0.013x |
|
BlackRock Latin American Investment Trust plc
LSE:BRLA
|
0.074x |
|
CardioComm Solutions Inc.
V:EKG
|
0.215x |
|
Sky Gold Corp
V:SKYG
|
-0.256x |
|
Ausmon Resources Ltd
AU:AOA
|
-0.232x |
Annual Cash Flow Conversion Efficiency for Protagenic Therapeutics (1995–2025)
The table below shows the annual cash flow conversion efficiency of Protagenic Therapeutics from 1995 to 2025. View latest Protagenic Therapeutics stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-4.69 Million | $-4.14 Million | 0.882x | +121.20% |
| 2024-12-31 | $1.01 Million | $-4.22 Million | -4.162x | -312.17% |
| 2023-12-31 | $3.67 Million | $-3.70 Million | -1.010x | -250.32% |
| 2022-12-31 | $6.92 Million | $-1.99 Million | -0.288x | -2.39% |
| 2021-12-31 | $9.94 Million | $-2.80 Million | -0.281x | -124.00% |
| 2020-12-31 | $-1.15 Million | $-1.35 Million | 1.173x | +52.50% |
| 2019-12-31 | $-634.37K | $-487.99K | 0.769x | -84.86% |
| 2018-12-31 | $-210.88K | $-1.07 Million | 5.080x | +548.78% |
| 2017-12-31 | $1.22 Million | $-1.38 Million | -1.132x | -145.87% |
| 2016-12-31 | $2.48 Million | $-1.14 Million | -0.460x | -169.54% |
| 2015-12-31 | $-571.00K | $-378.00K | 0.662x | -12.96% |
| 2015-06-30 | $-497.00K | $-378.00K | 0.761x | -93.26% |
| 2014-12-31 | $-70.00K | $-790.00K | 11.286x | 0.00% |
| 2013-12-31 | $-70.00K | $-790.00K | 11.286x | +59902.38% |
| 2012-12-31 | $-17.23 Million | $-324.00K | 0.019x | +101.37% |
| 2010-12-31 | $8.17 Million | $-11.25 Million | -1.377x | -1057.35% |
| 2009-12-31 | $25.35 Million | $-3.02 Million | -0.119x | -249.26% |
| 2008-12-31 | $54.65 Million | $4.36 Million | 0.080x | +125.80% |
| 2007-12-31 | $16.86 Million | $-5.21 Million | -0.309x | -140.58% |
| 2006-12-31 | $1.22 Million | $931.00K | 0.761x | +347.54% |
| 2004-12-31 | $2.74 Million | $-842.00K | -0.308x | -181.90% |
| 2003-12-31 | $4.98 Million | $1.87 Million | 0.376x | +106.06% |
| 2002-12-31 | $12.87 Million | $2.35 Million | 0.182x | +64.37% |
| 2001-12-31 | $13.57 Million | $1.50 Million | 0.111x | -56.20% |
| 2000-12-31 | $13.86 Million | $3.51 Million | 0.253x | +915.01% |
| 1999-12-31 | $13.27 Million | $331.00K | 0.025x | +180.14% |
| 1998-12-31 | $13.95 Million | $-434.00K | -0.031x | +81.20% |
| 1997-12-31 | $13.30 Million | $-2.20 Million | -0.166x | -406.58% |
| 1996-12-31 | $7.04 Million | $-230.00K | -0.033x | +59.11% |
| 1995-12-31 | $7.51 Million | $-600.00K | -0.080x | -- |
About Protagenic Therapeutics
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.